DREDGECAP

Cached SEC EDGAR filing history for PLUS THERAPEUTICS, INC. (PSTV), most recently a 10-Q dated 2026-05-15. 10 recent filings across 3 form types are indexed, each linked to the structured per-filing render and the EDGAR source. Every figure on this tab is extracted verbatim from the underlying SEC filing — no AI synthesis, no estimation.

PSTV Overview
10-QMay 15, 20265/15/26· Quarter Ended March 31, 2026· Q-End 3/31/26

PSTV10-Q Filing

Track for Alerts

Financial Highlights

Structured-data extract from the filer's SEC-tagged XBRL. Every value below is sourced from a labeled XBRL concept; hover any cell to see the exact source. No AI summarization, no paraphrasing.

Income Statement

ItemMar 31, 2026Mar 31, 2025YoY
Revenue$1.06M
Cost of Revenue
Operating Income (Loss)−$3.54M
Net Loss from Continuing Operations(derived)−$17.40M
Net Income (Loss) — Total−$17.40M

Balance Sheet

ItemMar 31, 2026Mar 31, 2025YoY
Total Assets$12.06M
Total Liabilities$35.70M
Stockholders' Equity−$23.64M
Accumulated Deficit−$510.88M
Cash and Cash Equivalents$9.87M
Shares Outstanding17.00M

Cash Flow

ItemMar 31, 2026Mar 31, 2025YoY
Operating Cash Flow−$6.17M
Source filings — every value above is extracted verbatim from these SEC submissions:
Current DredgeCap Risk Profile
8.5/10
HIGH RISK
Dilution Risk
EXTREME9.0/10
Liquidity Risk
HIGH8.0/10
Debt Toxicity
HIGH7.0/10
Profitability Risk
EXTREME9.5/10
Going Concern⚠️ Flagged
The risk profile above reflects the latest cached DredgeCap analysis for PSTV. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open PSTV's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on PSTV

Dilution Analysis
Debt Structure
Going Concern
Full Financials
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.